Hasten Pharma

Executive Summary

Hasten Pharma is a clinical-stage Chinese biopharmaceutical company specializing in novel small molecule therapeutics for metabolic and cardiovascular diseases, such as type 2 diabetes and atherosclerosis. Founded in 2015 and based in Shanghai, the company leverages medicinal chemistry and translational biology to develop candidates with improved safety and efficacy profiles. Although specific pipeline details are limited, Hasten Pharma is positioned to address high-prevalence conditions through its proprietary platform. As a private, Phase 2 company with 50-200 employees, it operates in a competitive landscape but targets significant unmet medical needs. The company's ability to advance its lead candidates through clinical trials and secure strategic partnerships will be key to its growth and valuation.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Data Readout for Lead Metabolic Candidate40% success
• Q4 2026Strategic Partnership for Cardiovascular Program30% success
• H1 2027IND Filing for New Pipeline Candidate50% success